z-logo
open-access-imgOpen Access
Inefficacy or Paradoxical Effect? Uveitis in Ankylosing Spondylitis Treated with Etanercept
Author(s) -
Bernd Raffeiner,
Francesca Ometto,
L. Bernardi,
Costantino Botsios,
Leonardo Punzi
Publication year - 2014
Publication title -
case reports in medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.2
H-Index - 20
eISSN - 1687-9627
pISSN - 1687-9635
DOI - 10.1155/2014/471319
Subject(s) - ankylosing spondylitis , etanercept , medicine , uveitis , tumor necrosis factor alpha , spondylitis , pharmacodynamics , adalimumab , tnf inhibitor , infliximab , dermatology , immunology , pharmacokinetics
Ankylosing spondylitis (AS) is presented with axial and peripheral articular involvement. Uveitis is a severe and rather specific manifestation of AS. Biologics targeting tumor necrosis factor (TNF) α are effective on both articular and ocular manifestations of disease. The occurrence of uveitis in patients that never had eye involvement or the relapse of uveitis is described during anti-TNF α treatment. The frequency of these events is slightly higher during therapy with etanercept. The available TNF α blockers show different pharmacokinetics and pharmacodynamics yielding different biological effects. There is an ongoing debate whether uveitis during anti-TNF α has to be considered as paradoxical effect or an inadequate response to therapy. Here, we present a case report and review what the evidences for the two hypotheses are.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom